Well StudiedWeight LossGrowth Hormone

Ipamorelin

Growth Hormone Secretagogue | Selective GHRP

Half-life

~2 hours

Chain length

5 amino acids

Reference frequency

1-3 times daily depending on goals (1x for longevity, 2-3x for performance)

Research overview

DoseGear research brief

Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produce consistent GH pulses without significant side effects common to other growth hormone releasing peptides.

Mechanism of action

Binds selectively to ghrelin receptors in pituitary gland, stimulating natural GH release with direct systemic delivery via injection, consistent GH pulse stimulation, no significant cortisol or prolactin elevation, and minimal hunger response.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic selective growth-hormone-secretagogue peptide.

What it is researched for

Growth-hormone pharmacology, bone research, and postoperative-ileus trials through ghrelin/GHS-R1a agonism.

Research observation window

A human IV study measured GH peak at about 0.67 hours; an ileus trial treated for up to seven days without significant efficacy.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
General Health & Longevity	200mcg	1x daily before bed	SubQ
Body Composition	250-300mcg	2x daily (morning, pre-workout)	SubQ
Athletic Performance	200-250mcg	2-3x daily	SubQ
Sleep & Recovery	200mcg	1x daily 30min before bed	SubQ
Anti-Aging Protocol	200-250mcg	1-2x daily	SubQ

Reference cycle

3-6 months

Reference storage

Lyophilized: Room temperature; Reconstituted: 2-8°C, use within 28 days

Safety context

Reported side effects

Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)

Contraindications & cautions

Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease

Scientific references

01
Ipamorelin, the first selective growth hormone secretagogue
Scientific citationIpamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (1998).
02
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Scientific citationPharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. British Journal of Clinical Pharmacology (1999).
03
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
Scientific citationIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research (1999).
04
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats
Scientific citationThe growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Calcified Tissue International (2001).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Growth Hormone